.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
AstraZeneca
Covington
Queensland Health
Express Scripts
Deloitte
Farmers Insurance
Merck
Colorcon

Generated: November 19, 2017

DrugPatentWatch Database Preview

Cefixime - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cefixime and what is the scope of cefixime freedom to operate?

Cefixime
is the generic ingredient in two branded drugs marketed by Lederle, Lupin Pharms, Aurobindo Pharma Ltd, Belcher Pharms Llc, and Lupin Ltd, and is included in eleven NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Cefixime has two patent family members in two countries.

There are fourteen drug master file entries for cefixime. Eight suppliers are listed for this compound.

Pharmacology for cefixime

Medical Subject Heading (MeSH) Categories for cefixime

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
SUPRAX
cefixime
TABLET, CHEWABLE;ORAL065380-001Oct 25, 2010RXNoNo► Subscribe► Subscribe► Subscribe
Lupin Pharms
SUPRAX
cefixime
FOR SUSPENSION;ORAL065129-001Feb 23, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
SUPRAX
cefixime
CAPSULE;ORAL203195-001Jun 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Lederle
SUPRAX
cefixime
TABLET;ORAL050621-002Apr 28, 1989DISCNYesNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
CEFIXIME
cefixime
FOR SUSPENSION;ORAL204835-001Apr 14, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Belcher Pharms Llc
CEFIXIME
cefixime
FOR SUSPENSION;ORAL206939-001Feb 6, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Belcher Pharms Llc
CEFIXIME
cefixime
FOR SUSPENSION;ORAL206938-002Feb 6, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
CEFIXIME
cefixime
FOR SUSPENSION;ORAL204835-002Apr 14, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Belcher Pharms Llc
CEFIXIME
cefixime
FOR SUSPENSION;ORAL206938-001Feb 6, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
SUPRAX
cefixime
TABLET, CHEWABLE;ORAL065380-002Oct 25, 2010RXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: cefixime

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905Pharmaceutical compositions of Cefixime► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cefixime

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2007119249► Subscribe
Germany112007000920► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Express Scripts
Accenture
Moodys
Colorcon
UBS
AstraZeneca
Cipla
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot